Conceptual illustration of C’ dot nanoparticles adapted with HER2-targeting antibody fragments (dark blue and green) and cancer-killing drugs (teal), entering a tumor cell via HER2 receptors (orange).
A novel cancer therapeutic, combining antibody fragments with molecularly engineered nanoparticles, permanently eradicated gastric cancer in treated mice, a multi-institutional team of researchers found.
The results of the “hit and run” drug delivery system, published in the March issue of Advanced Therapeutics, were the culmination of more than five years of collaboration between Cornell, the Memorial Sloan Kettering Cancer Center (MSKCC) and biopharmaceutical company AstraZeneca.
“I’ve seen beautiful results before, but I’ve never seen something that eradicates a tumor like this,” said study co-lead author Dr. Michelle Bradbury, MSKCC director of intraoperative imaging and professor of radiology at Weill Cornell Medicine.
The other co-lead authors are Ulrich Wiesner, the Spencer T. Olin Professor in the Department of Materials Science and Engineering, at Cornell Engineering; and J. Anand Subramony, vice president of protein engineering research and development at AstraZeneca at the time of the study.
Targeted cancer treatments such as antibody and nanoparticle therapies have seen narrow clinical use because of each therapy’s limitations, but the new therapeutic – an evolution of what the researchers call Cornell prime dots, or C’ dots – combines the best attributes of both into an ultrasmall, powerfully effective system.
As silica nanoparticles just 6 nanometers in size, C’ dots are small enough to penetrate tumors and safely pass through organs once injected into the body. Wiesner first developed them more than 15 years ago and, in collaboration with Bradbury, published a 2018 study that found an antibody fragment-nanoparticle hybrid to be especially effective in finding tumors.
This collaborative work with AstraZeneca set off the search for a new, molecularly engineered therapeutic version of this immuno-conjugate.
AstraZeneca “site engineered” fragments of antibodies so they would effectively attach to the C’ dots and target HER2 proteins associated with gastric cancer. The team optimized fragment conjugation to the C’ dot surface, along with specialized inhibitor drugs developed by AstraZeneca. This enabled the nanoparticles to carry about five times more drugs than most antibodies.
The final product was a version of C’ dots, armed with cancer-targeting antibody fragments and a large drug payload, all packed into a sub-7-nanometer, drug-immune conjugate therapy – a first of its kind in that size class, according to the researchers.
“We describe the mode of action as ‘hit and run,’” Wiesner said, “because the C’ dots either target the tumor microenvironment and kill the tumor cells or get safely cleared out of the body via renal clearance as a result of their small size, thereby minimizing off-target accumulation and associated side effects and toxicity.”
Mice with gastric cancer received three doses of the therapeutic. Not only did the treatment eradicate the disease in every mouse, but there was no evidence of tumor recurrence after nearly 200 days.
“Usually you’d have to couple the treatment with other therapies to see those kind of long-term results,” Bradbury said. “It showed that the very detailed, careful work of this team – the years spent on the stoichiometry and the surface chemical developments – it paid off.”
Bradbury underscored the versatility of the C’ dots platform, and said she envisions it being used not as a replacement for antibody treatments, but as a complementary tool that can be adapted to different types of cancers and other specific needs of patients.
“C’ dots have become unusually efficacious and safe in treating cancer. They completely obliterated the tumor, even at the cellular level,” said Wiesner. “This is what we ultimately had hoped for and it further supports our earlier decision to bet on therapeutic C’ dot applications.”
Wiesner and Bradbury said the research behind the new C’ dot therapeutic will be continued by Elucida Oncology, a startup company they founded to help bring the technology to market. They said that while Elucida is not using antibody fragments in their current clinical trial of C’ dots, the work will help them build new conjugates that can potentially utilize such fragments in future trials.
Original Article: Antibody fragment-nanoparticle therapeutic eradicates cancer
More from: Cornell University College of Engineering | Memorial Sloan Kettering Cancer Center
The Latest Updates from Bing News
Go deeper with Bing News on:
Cornell prime dots
- Israel’s war on Gaza live: ‘Biggest catastrophe’ facing Palestinians
The Israeli military’s chief of staff approves plans for the “continuation of war” as hardline ministers warn Prime Minister Netanyahu his government will collapse if a truce is agreed on. At least 34 ...
- Israel’s war on Gaza live: US campus protests intensify amid truce push
Hamas official Khalil al-Hayya says the Palestinian group is reviewing a new Israeli truce proposal, as Israel’s foreign minister says a planned invasion of Rafah would be “suspended” if a prisoner ...
Go deeper with Bing News on:
C’ dots
- Kia EV9 wins coveted Red Dot: ‘Best of the Best’ Award
Kia EV9 named 'Best of the Best' in Cars and Motorcycles category at Red Dot Award: Product Design 2024 Global design competition recognizes influential power of Kia’s ‘Opposites United’ ...
- IATA Frustrated With New US DOT Consumer Protection Rules
The“Refunds and Other Consumer Protection Rule” will force airlines to provide automatic refunds for delays or cancellations, irrespective of the cause of the disruption. The“Enhancing Transparency of ...
- DOT vows more support for Mindanao tourism
The Department of Tourism (DOT) is pushing all buttons to bring international and local tourists to visit Mindanao as the peace and security situation in the region has tremendously improved compared ...
- C-DOT and IIT-Jodhpur sign 5G partnership, to build systems using AI
C-DOT and IIT-J signed an agreement for AI-based 5G network management under TTDF, aiming to impact transportation, smart cities, and future 6G standa ...
- ‘The Students Are More United Than Ever!’: Multiple D.C. Universities create pro-Palestine encampment at George Washington University
Students from George Washington University, Georgetown University, Howard University, Galludet University, University of Maryland, George Mason University, and American University are allegedly ...